Small Cap Feast

3rd May 2024

Dish of the day
No Joiners today
Off the menu
No leavers today


Dish Of The Day:


Admissions: 

TheWorks (WRKS.L) has transferred to AIM from the Premium Segment of the Main Market. 

Electric Guitar (ELEG.L) has transferred to AIM from the Standard Segment of the Main Market.

Delistings: 







Whats baking in the oven?

Potential Initial Public Offerings:


Reverse Takeovers:


Change of Market:

Dual Listing :


Banquet Buffet

Angle plc 15.5p £40.4m (AGL.L)

The liquid biopsy company with innovative circulating tumour cell solutions for use in research, drug development and clinical oncology announces that it has signed a supplier agreement to develop a Parsortix-based Androgen Receptor detection assay for use in prostate cancer studies. The supplier agreement reported here is with AstraZeneca. This follows an earlier agreement to develop a methodology for CTC micronuclei detection using the Company's DNA Damage Response assay, announced on 24 April 2024. Under the terms of this agreement, worth £550k to ANGLE, the Company will develop a CTC-based AR assay. Assay development will take place in the ANGLE's UK laboratories, with project completion expected in Q1 2025.

Duke Capital 31.75p £131.9m (DUKE.L)

The provider of hybrid capital solutions for SME business owners in Europe and North America announces a follow-on investment of £4m into its existing capital partner, BPVA Limited. This investment will enable BPVA to complete its latest acquisition as well as reorganise the shareholder base through the buyout of certain minority investors. Duke's funds will be used to facilitate BPVA's acquisition of Sabeo Holdings Ltd, an IT contracting and talent acquisition business, as well to complete a reconfiguration of the shareholding structure of the BPVA entity.

Essentially Group 52.5p £26.9m (AQSE: ESSN)

As announced on 8 March 2024, Essentially' s wholly owned subsidiary, Essentially Holdings Limited, a company registered in Abu Dhabi Global Market has entered into a binding share purchase agreement for the acquisition of the entire share capital of Best of Latin Foodstuff Trading LLC from the sole shareholder of Best of Latin, Catalina Oñate for a total consideration of £1.94m. The long stop date for the completion of the acquisition was 3 May 2024. The parties to the Share Purchase Agreement have agreed an extension of this long stop date to 31 May 2024 to allow additional time to obtain the approval from the Department of Economic Development in Dubai UAE.

i-nexus Global 2.75p £0.8m (INX.L)

The cloud-based Strategy software solutions designed for the Global 5000 announces its unaudited results for the six months ended 31 March 2024. Revenue increased 4% to £1.74m (H1 2023: £1.67m). Adjusted EBITDA loss was reduced to 53k (H1 2023: loss £358k). Cash and cash equivalents increased to £250k (H1 2023: £147k) due to effective working capital management measures. i-nexus is well positioned to capitalise on the continued rise in interest for a strategy execution software solution as companies across all industries accelerate the digitisation of mission-critical processes.

Mirriad Advertising 1.3p £6.4m (MIRI.L)

The virtual in-content advertising and virtual product placement company announces, further to the announcement on 2 May 2024 regarding the launch of a proposed placing by way of an accelerated bookbuild, that the accelerated bookbuild has closed and the Company has conditionally raised gross proceeds of £6.12m at a price of 1.25p per new Ordinary Share. Assuming the Directors' Subscription proceeds as intended, the Company has conditionally raised total gross proceeds of £6.3m from the Placing and Directors' Subscription.

Pharos Energy 23p £96.7m (PHAR.L)

The independent energy company announces that Marianne Daryabegui, independent Non-Executive Director, will retire from the Board of Directors of Pharos at the conclusion of the Company's forthcoming annual general meeting on 23 May 2024. Accordingly, resolution 6 within the notice of the AGM, proposing the reappointment of Marianne Daryabegui, will be withdrawn from consideration at the meeting.

Physiomics * 1.3p £1.8m (PYC.L)

The mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, provides a trading update. Despite a strong pipeline of potential new business, several large contracts have taken longer than expected to be signed and as a result, the total income for the financial year ending 30 June 2024 (FY24) is now expected to fall in the range of £600k-650k. The Company is in the final stages of negotiation for two projects for a total value of approximately £350k. Whilst the Board anticipates these two projects to be signed in FY24, the majority of the revenue is now expected be recognised in the next financial year ending 30 June 2025 (FY25), and accordingly the Board's expectations for FY25 revenues have been correspondingly increased. The Company has, to date, secured £225k of revenue in respect of FY25 which is expected to increase to over £0.5m on the signing of the two aforementioned contracts.

Prospex Energy 5.8p £19.3m (PXEN.L))

The investment company focused on European gas and power projects, announces an update from the Selva Malvezzi production concession in Italy following the publication by Po Valley Energy (PVE) of its Q1 2024 activity report. Po Valley Operations Pty Limited, a wholly owned subsidiary of PVE, is the operator of the Selva Malvezzi production concession and has a 63% working interest, while Prospex has the remaining 37% working interest. The weighted average gas sales price for the quarter was EUR0.30/scm. Gross Quarterly production was 6,385,255 scm (2,362,544 scm net to Prospex) and gross revenue for the quarter was EUR1.9m (EUR0.7m net to Prospex).

Roadside Real Estate 9.5p £13.6m (ROAD.L)

The real estate business focused on building and scaling a high-quality portfolio of modern roadside retail assets, including modern EV charging infrastructure, announces its audited results for the 15-month period to 30 September 2023. Revenue decreased to £0.1m (2022: £4.3m) and loss after tax increased to £10.2m (2022: loss £9.5m). Net cash increased to £0.0m (2022: net debt £0.4m). The Group has improved liquidity following the issue of a loan note in April 2024, refinancing and extending its debt facilities alongside the proceeds from the Cambridge Sleep Sciences (CSS) stake sale. Roadside is currently focused on two further development assets in Swindon and Spalding.

Xeros Technology Group 1.375p £7.2m (XSG.L)

The creator of technologies that reduce the impact of clothing on the planet, confirms that under the terms of a Board Observer Agreement dated 2 May 2024 between the Company and Amati Global Investors Limited, it has appointed Paul Jourdan of Amati as a board observer at an annual fee of £20,000, payable to Amati. The entering into of the Observer Agreement by the Company with Amati is a related party transaction for the purposes of the AIM Rules by virtue of Amati being the appointed Fund Manager of Amati AIM VCT plc, a 12.8% shareholder of Xeros.

.

3 May 2024
*A corporate client of Hybridan LLP or retained by Hybridan LLP for certain services
** Arranged by most recent first
*** Alphabetically arranged

STAY INFORMED

Our daily digest of news from UK listed Small and Mid caps straight to your Inbox.

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.

© Copyright 2024 - Hybridan | Website by Boxed Up Media
First Visit
bookcrossmenu linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram